Sorry, you lost me there. If B were merely a diversion to buy time forK, then the current B trial would not be 50% complete. B would not be testing 4 arms. B would not also advancing for OM.
I agree that the markey views it as a weakness, but the market can be irrational. When the market acts irrationally by greatly discounting what should be essentially a doubling in cap, then it also reacts irrationally and reactively once news confirms even greater value after a long period of depressed cap.
The longer the market fails to add B to CTIX value, the greater the irrational upside explosion once results begin to leak.
$4.5 million for ABSSSI and $3 million for Oral Mucositis... That's one expensive diversion. I disagree with your "objective" argument. I sense confidence.
Market Data 
Markets 
AI
